Global Blood Screening Industry

Global Blood Screening Industry

  • February 2020 •
  • 346 pages •
  • Report ID: 5798062 •
  • Format: PDF
Blood Screening market worldwide is projected to grow by US$1.8 Billion, driven by a compounded growth of 9.2%. Nucleic Acid Test (NAT), one of the segments analyzed and sized in this study, displays the potential to grow at over 9.2%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$1.7 Billion by the year 2025, Nucleic Acid Test (NAT) will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 7.8% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$60.3 Million to the region’s size and clout in the next 5 to 6 years. Over US$52.7 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Nucleic Acid Test (NAT) will reach a market size of US$78.4 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 13.7% over the next couple of years and add approximately US$504.2 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others,
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols International SA
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.